CANCER AND NEW PROSPECTIVE TO TREAT CANCER
DOI:
https://doi.org/10.22159/ijcpr.2023v15i6.3078Keywords:
Cancer, Treatment, Stem cell, Targeted drugs, Ablation, Natural antioxidants and gene therapyAbstract
Cancer is a condition when a few of the body's cells grow out of control and spread across other bodily regions. In the millions of cells that make up the human body, cancer may develop practically anywhere. Human cells often divide (via a process known as cell growth and multiplication) to create new cells when the body requires them. New cells replace old ones when they die as a result of ageing or injury. Aside from recent significant advancements in stem cell treatment, targeted therapy, ablation therapy, nanoparticles, natural antioxidants, radionics, chemodynamic therapy, sonodynamic therapy, and ferroptosis-based therapy, traditional treatment modalities like surgery, chemotherapy, and radiotherapy are still in use. Oncology practices today concentrate on creating effective and secure cancer nanomedicines. Targeting both primary and metastatic cancer foci, stem cell treatment has demonstrated remarkable success in regenerating and repairing sick or damaged tissues, and nanoparticles have introduced novel diagnostic and therapeutic possibilities. The development and spread of particular cancer cells can be prevented by targeted treatment, which also protects good cells from harm. Ablation treatment has become a less invasive method for freezing or burning tumours without performing open surgery. Natural antioxidants have shown promise in locating free radicals and counteracting their damaging effects, perhaps treating or preventing cancer. Clinical trials are being conducted on a number of innovative technologies, some of which have already received approval. A summary on current developments and discoveries in cancer therapy was provided in this review.
Downloads
References
Martland HS, Conlon P, Knef JP. Some unrecognized dangers in the use and handling of radioactive substances: with especial reference to the storage of insoluble products of radium and mesothorium in the reticulo-endothelial system. J Am Med Assoc. 1925 Dec 5;85(23):1769-76. doi: 10.1001/jama.1925.02670230001001.
Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby Secretan B, El Ghissassi F. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011 Dec 21;103(24):1827-39. doi: 10.1093/jnci/djr483, PMID 22158127.
Ward E, Carpenter A, Markowitz S, Roberts D, Halperin W. Excess number of bladder cancers in workers exposed to Ortho-toluidine and aniline. J Natl Cancer Inst. 1991 Apr 3;83(7):501-6. doi: 10.1093/jnci/83.7.501, PMID 2005633.
Costello J, Graham WG. Vermont granite workers’ mortality study. Am J Ind Med. 1988;13(4):483-97. doi: 10.1002/ajim.4700130408, PMID 2834946.
Garshick E, Laden F, Hart JE, Rosner B, Smith TJ, Dockery DW. Lung cancer in railroad workers exposed to diesel exhaust. Environ Health Perspect. 2004 Nov;112(15):1539-43. doi: 10.1289/ehp.7195, PMID 15531439.
Steenland K, Schnorr T, Beaumont J, Halperin W, Bloom T. Incidence of laryngeal cancer and exposure to acid mists. Br J Ind Med. 1988 Nov 1;45(11):766-76. doi: 10.1136/oem.45.11.766, PMID 3203082.
Fingerhut MA, Halperin WE, Marlow DA, Piacitelli LA, Honchar PA, Sweeney MH. Cancer mortality in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. N Engl J Med. 1991 Jan 24;324(4):212-8. doi: 10.1056/NEJM199101243240402, PMID 1985242.
Boffetta P, Fryzek JP, Mandel JS. Occupational exposure to beryllium and cancer risk: a review of the epidemiologic evidence. Crit Rev Toxicol. 2012 Feb 1;42(2):107-18. doi: 10.3109/10408444.2011.631898, PMID 22276590.
Koshurnikova NA, Bolotnikova MG, Ilyin LA, Keirim-Markus IB, Menshikh ZS, Okatenko PV. Lung cancer risk due to exposure to incorporated plutonium. Radiat Res. 1998 Apr 1;149(4):366-71. doi: 10.2307/3579699, PMID 9525501.
Baverstock K, Egloff B, Pinchera A, Ruchti C, Williams D. Thyroid cancer after Chernobyl. Nature. 1992 Sep 3;359(6390):21-2. doi: 10.1038/359021b0, PMID 1522880.
Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981 Feb 19;304(8):441-7. doi: 10.1056/NEJM198102193040801, PMID 7005681.
Boice JD, Greene MH, Killen Jr JY, Ellenberg SS, Fraumeni Jr JF, Keehn RJ. Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU)-evidence of a dose-response effect. N Engl J Med. 1986 Jan 1;314(2):119-20. doi: 10.1056/NEJM198601093140214, PMID 3941685.
Penn I, Brunson ME. Cancers after cyclosporine therapy. In: Transplantation Proc. 1988 Jun 1;20(3)Suppl 3:885-92.
Hardell L. Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet. 1988 Dec 17;2(8625):1432. doi: 10.1016/s0140-6736(88)90629-0, PMID 2904564.
Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987;70(5):1412-7, PMID 2822173.
Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert W. Leukemia following chemotherapy for ovarian cancer. N Engl J Med. 1990 Jan 4;322(1):1-6. doi: 10.1056/NEJM199001043220101, PMID 2104664.
Newhouse ML, Pearson RM, Fullerton JM, Boesen EA, Shannon HS. A case-control study of carcinoma of the ovary. J Epidemiol Community Health. 1977 Sep 1;31(3):148-53. doi: 10.1136/jech.31.3.148.
Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med. 1980 Mar 6;302(10):551-4. doi: 10.1056/NEJM198003063021004, PMID 7351890.
Calabrese EJ, Blain RB. The hormesis database: the occurrence of hormetic dose responses in the toxicological literature. Regul Toxicol Pharmacol. 2011 Oct 1;61(1):73-81. doi: 10.1016/j.yrtph.2011.06.003, PMID 21699952.
Plimmer HG. The parasitic theory of cancer. Br Med J. 1903 Dec 12;2(2241):1511-5. doi: 10.1136/bmj.2.2241.1511, PMID 20761234.
Krumbhaar EB. Experimental cancer, an historical retrospect: from the laboratories of the Philadelphia General Hospital. Ann Med Hist. 1925;7(2):132-40, PMID 33944403.
Peyton RO. Transmission of a malignant new growth by means of a cellfree filtrate. Joun AMA. 1911 Jan;21:198.
Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med. 1911 Apr 4;13(4):397-411. doi: 10.1084/jem.13.4.397, PMID 19867421.
Yamagiwa K, Ichikawa K. Experimental study of the pathogenesis of carcinoma. CA Cancer J Clin. 1977 May;27(3):174-81. doi: 10.3322/canjclin.27.3.174, PMID 406018.
Blackadar CB. Historical review of the causes of cancer. World J Clin Oncol. 2016 Feb 2;7(1):54-86. doi: 10.5306/wjco.v7.i1.54, PMID 26862491.
Kennaway EL, Hieger I. Carcinogenic substances and their fluorescence spectra. Br Med J. 1930 Jun 6;1(3622):1044-6. doi: 10.1136/bmj.1.3622.1044, PMID 20775497.
Miller EC, Miller JA. Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer. 1981 May 15;47(10):2327-45. doi: 10.1002/1097-0142(19810515)47:10<2327::aid-cncr2820471003>3.0.co;2-z, PMID 7272889.
Melick WF, Escue HM, Naryka JJ, Mezera RA, Wheeler EP. The first reported cases of human bladder tumors due to a new carcinogen-xenylamine. J Urol. 1955 Dec;74(6):760-6. doi: 10.1016/S0022-5347(17)67344-0, PMID 13278983.
Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western cape province. Br J Ind Med. 1960 Oct 1;17(4):260-71. doi: 10.1136/oem.17.4.260, PMID 13782506.
Baris YI, Sahin AA, Ozesmi M, Kerse I, Ozen E, Kolacan B. An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax. 1978 Apr 1;33(2):181-92. doi: 10.1136/thx.33.2.181, PMID 663877.
Vigliani EC, Saita G. Benzene and leukemia. N Engl J Med. 1964 Oct 22;271(17):872-6. doi: 10.1056/NEJM196410222711703, PMID 14185112.
Imam SS, Agarwal S. A pragmatic approach to treat lung cancer through loading theaflavin-3,3’-digallate and epigallocatechin gallate in spanlastic. Asian J Pharm Clin Res. 2021 Nov 7;14(11):1-8.
Imam SS. The future of non-invasive ways to treat cancer. Int J Pharm Sci Res. 2021;12(8):4684-96.
Imam SS, Imam ST, Mdwasifathar KR, Ammar MY. Interaction between ace2 and sars-Cov2, and use of EGCG and theaflavin to treat COVID 19 in initial phases. Int J Curr Pharm Res. 2022 Mar;14(2):5-10.
Imam SS, Sharma R. Natural compounds promising way to treat lung cancer. Int J Pharm Res Appl. 2023;8(2):552-8.
Imam SS, Sharma S, Kumari D, Khan S, Pathak P, Katiyar D. An expedient approach to treat asthma through nonsteroidal, natural transferosomes aerosol system. Innovare Journal of Medical Sciences. 2022;10(6):7-11.
Imam SS, Imam ST, Agarwal S, Kumar R, Ammar MY, Athar MW. Lung cancer therapy using naturally occurring products and nanotechnology. Innovare Journal of Medical Sciences. 2022;10(4):1-5.
Imam ST, Imam SS. The cream which relieves the pain of menstrual cramps without interfering with the hormones or period cycle. Res J Pharm Technol. 2023;16(3):1239-6.
Imam SS. Topical formulation constituted with transferosomes for the treatment of non-melanoma skin cancer. Asian J Pharm Clin Res 2023 May;16(5):27-32.
Ganesh K, Massague J. Targeting metastatic cancer. Nat Med. 2021 Jan;27(1):34-44. doi: 10.1038/s41591-020-01195-4, PMID 33442008.
Merriel SWD, Ingle SM, May MT, Martin RM. Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors for prostate cancer progression using primary care data. BMJ Open. 2021 Feb 1;11(2):e044420. doi: 10.1136/bmjopen-2020-044420, PMID 33579772.
Roy A, Li SD. Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Nov;8(6):891-908. doi: 10.1002/wnan.1406, PMID 27038329.
Bayat Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B. Combination therapy in combating cancer. Oncotarget. 2017 Jun 6;8(23):38022-43. doi: 10.18632/oncotarget.16723, PMID 28410237.
Abbas Z, Rehman S. An overview of cancer treatment modalities. Neoplasm. 2018 Sep 19;1:139-57.
El-Hussein A, Manoto SL, Ombinda Lemboumba S, Alrowaili ZA, Mthunzi Kufa P. A review of chemotherapy and photodynamic therapy for lung cancer treatment. Anticancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry Anticancer Agents). 2021 Jan 1;21(2):149-61.
Charmsaz S, Collins DM, Perry AS, Prencipe M. Novel strategies for cancer treatment: highlights from the 55th IACR annual conference. Cancers (Basel). 2019;11(8). doi: 10.3390/cancers11081125, PMID 31394729.
Arruebo M, Vilaboa N, Saez Gutierrez B, Lambea J, Tres A, Valladares M. Assessment of the evolution of cancer treatment therapies. Cancers. 2011 Aug 12;3(3):3279-330. doi: 10.3390/cancers3033279, PMID 24212956.
Moses MA, Brem H, Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell. 2003 Nov 1;4(5):337-41. doi: 10.1016/s1535-6108(03)00276-9, PMID 14667500.
Mondal J, Panigrahi AK, Khuda Bukhsh AR. Conventional chemotherapy: problems and scope for combined therapies with certain herbal products and dietary supplements. Austin J Mol Cell Biol. 2014;1(1):1-10.
Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 2019 Sep 1;76(17):3323-48. doi: 10.1007/s00018-019-03125-1, PMID 31055643.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76. doi: 10.1016/j.cell.2006.07.024, PMID 16904174.
Ouyang X, Telli ML, Wu JC. Induced pluripotent stem cell-based cancer vaccines. Front Immunol. 2019 Jul 8;10:1510. doi: 10.3389/fimmu.2019.01510, PMID 31338094.
Lin W, Huang L, Li Y, Fang B, Li G, Chen L. Mesenchymal stem cells and cancer: clinical challenges and opportunities. BioMed Res Int. 2019 May 8;2019:2820853. doi: 10.1155/2019/2820853, PMID 31205939.
Chang JC. Cancer stem cells: role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine. 2016 Sep;95(1)Suppl 1:S20-5. doi: 10.1097/MD.0000000000004766, PMID 27611935.
Vakhshiteh F, Atyabi F, Ostad SN. Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy. Int J Nanomedicine. 2019 Apr 23;14:2847-59. doi: 10.2147/IJN.S200036, PMID 31114198.
Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol. 2010 Jul 10;28(20):3344-51. doi: 10.1200/JCO.2009.23.3429, PMID 20498405.
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017 Oct 1;23(10):1124-34. doi: 10.1038/nm.4409, PMID 28985214.
Bailey KM, Wojtkowiak JW, Hashim AI, Gillies RJ. Targeting the metabolic microenvironment of tumors. Adv Pharmacol. 2012 Jan 1;65:63-107. doi: 10.1016/B978-0-12-397927-8.00004-X, PMID 22959024.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691, PMID 15175435.
Jacobs SA. Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin’s lymphoma: current status and future prospects. Biologics. 2007 Sep 1;1(3):215-27, PMID 19707332.
Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol. 2012 Feb 10;52:549-73. doi: 10.1146/annurev-pharmtox-010611-134532, PMID 22235862.
Liu Y, Cao CS, Yu Y, Si YM. Thermal ablation in cancer. Oncol Lett. 2016 Oct 1;12(4):2293-5. doi: 10.3892/ol.2016.4997, PMID 27703520.
Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998 Nov 1;37(3):171-86. doi: 10.1006/cryo.1998.2115, PMID 9787063.
Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL. The ”bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993 Nov 1;53(21):5274-83. PMID 8221662.
Subhan MA, Torchilin VP. siRNA based drug design, quality, delivery and clinical translation. Nanomedicine. 2020 Oct 1;29:102239. doi: 10.1016/j.nano.2020.102239, PMID 32544449.
Xu CF, Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci. 2015 Feb 1;10(1):1-12. doi: 10.1016/j.ajps.2014.08.011.
Kim HS, Song IH, Kim JC, Kim EJ, Jang DO, Park YS. In vitro and in vivo gene-transferring characteristics of novel cationic lipids, DMKD (O,O’-dimyristyl-N-lysyl aspartate) and DMKE (O, O-dimyristyl-N-lysyl glutamate). J Control Release. 2006 Oct 10;115(2):234-41. doi: 10.1016/j.jconrel.2006.08.003, PMID 16989919.
Urban Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethyleneimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005 Mar;12(5):461-6. doi: 10.1038/sj.gt.3302425, PMID 15616603.
Bernardini S, Tiezzi A, Laghezza Masci V, Ovidi E. Natural products for human health: a historical overview of the drug discovery approaches. Nat Prod Res. 2018 Aug 18;32(16):1926-50. doi: 10.1080/14786419.2017.1356838, PMID 28748726.
Liu Y, Tang ZG, Lin Y, Qu XG, Lv W, Wang GB. Effects of quercetin on proliferation and migration of human glioblastoma U251 cells. Biomed Pharmacother. 2017 Aug 1;92:33-8. doi: 10.1016/j.biopha.2017.05.044, PMID 28528183.
Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol. 2019 Nov 28;12(1):126. doi: 10.1186/s13045-019-0817-3, PMID 31779642.
Vaiserman A, Koliada A, Zayachkivska A, Lushchak O. Nanodelivery of natural antioxidants: an anti-aging perspective. Front Bioeng Biotechnol. 2019;7:447. doi: 10.3389/fbioe.2019.00447, PMID 31998711.
Published
How to Cite
Issue
Section
Copyright (c) 2023 SHIRAZ MEHDI, AYUSH CHAUHAN, AYUSH DHUTTY
This work is licensed under a Creative Commons Attribution 4.0 International License.
